עמוד 1 מ 98 תוצאות
OBJECTIVE
To report 12-year follow-up experience with topical mitomycin chemotherapy for diffuse and multifocal primary acquired melanosis (PAM) with atypia and conjunctival melanoma.
METHODS
Interventional case series of 16 patients. Mitomycin was a primary treatment for residual epithelial disease
OBJECTIVE
To report our results of 12 consecutive patients with conjunctival primary acquired melanosis (PAM) with atypia who were treated by topical Mitomycin C (MMC).
METHODS
Retrospective interventional consecutive case series.
METHODS
Twelve patients with PAM with atypia in one of their eyes who
OBJECTIVE
To describe the incidence, characteristics, risk factors, and clinical outcome of limbal stem cell deficiency (LSCD) resulting from topical treatment with mitomycin C (MMC) for primary acquired melanosis (PAM) with atypia.
METHODS
Retrospective, observational case series.
METHODS
Patients
OBJECTIVE
To evaluate clinical features and risks for transformation of conjunctival primary acquired melanosis (PAM) into melanoma.
METHODS
Retrospective chart review and Kaplan-Meier estimates of times to PAM enlargement, recurrence, and transformation into melanoma.
METHODS
PAM enlargement,
OBJECTIVE
To evaluate the clinical features and risks for transformation of conjunctival primary acquired melanosis (PAM) into melanoma.
METHODS
Noncomparative case series.
METHODS
Three hundred eleven eyes with conjunctival PAM without melanoma at initial examination from a single-center tertiary
Laser treatment has emerged as a common treatment modality for acquired bilateral nevus of Ota-like macules (ABNOM). To identify the ratio of melasma induction and exacerbation before and after laser therapy for ABNOM and to observe the risk factors related to the induction and exacerbation of
A case is reported of a patient in whom an intracranial extracerebral melanoma developed in association with a life-long nevus of Ota. Melanotic pigmentation of the skull, periosteum, and meninges beneath the nevus was found at operation.
The Q-switched ruby laser at 694 nm, a wavelength well absorbed by melanin relative to other optically absorbing structures in skin, causes highly selective destruction of pigment-laden cells. In addition, the 20- to 40-ns pulse duration produced by this laser approximates the thermal relaxation
OBJECTIVE
To evaluate cell growth and the pattern of p53 suppressor gene expression in atypical primary acquired melanosis (PAM) and in recurrent conjunctival melanoma.
METHODS
Eighteen specimens of PAM with atypia and 24 specimens, comprising early and late lesions, from 12 patients with
A 66-year-old woman was treated with excision and cryotherapy for recurrent primary acquired melanosis (PAM) with atypia of the right conjunctiva. Four years later, she developed a melanoma of the ipsilateral inferior turbinate and nasolacrimal duct. She was treated with right medial maxillectomy
OBJECTIVE
To review the diagnostic categories of a group of conditions referred to as "primary acquired melanosis."
METHODS
Literature review on the subject and proposal of an alternative diagnostic schema with histopathologic and immunohistochemical illustrations.
METHODS
Standard
BACKGROUND
The authors describe an amelanotic malignant melanoma of the conjunctiva in association with primary acquired melanosis (PAM) sine pigmento, and highlight the clinical and pathologic features of this rare entity.
METHODS
Histopathologic and immunohistochemical studies were performed on a
This essay places the concept of "primary acquired melanosis" of the conjunctiva in historical perspective and shows that it and its analogs, namely, lentigo-melanosis (Hutchinson), melanotic freckle (Hutchinson), melanose circonscrite precancereuse (Dubrueilh), melanotische precancerose (Miescher),
A condition clinically identical to human conjunctival primary acquired melanosis (PAM) was induced in 16 of 20 Dutch (pigmented) rabbits after weekly topical 60-microliters applications of a 1% solution of 7,12-dimethylbenz[a]anthracene (DMBA) in acetone. Pigment stippling appeared in the
A case of primary acquired melanosis of the conjunctiva primarily treated with topical mitomycin chemotherapy is presented. The patient underwent treatment with one 2-week course of topical mitomycin 0.02% four times daily, followed 4 weeks later by a 2-week course of topical mitomycin 0.04% four